Wednesday, July 8, 2026

pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS

Arcus Biosciences

Arcus Biosciences clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
Status
Public
HQ
3928 Point Eden Way, Hayward, California 94545, US
Founded
2015
Employees
655
Programs
53
Drugs
25
Patents
30
Intelligence · Clinical Programs

Arcus Biosciences projects

22 ClinicalTrials.gov programs sponsored by Arcus Biosciences.

Arcus Biosciences has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AB308

    Arcus Biosciences

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  2. AB598

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial
  3. AB680

    Arcus Biosciences

    Advanced Pancreatic Cancer

    phase 1 small molecule active

    1 trial
  4. AB680

    Arcus Biosciences

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  5. AB801

    Arcus Biosciences

    Cancer

    phase 1 small molecule completed

    1 trial
  6. AB801

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial
  7. ARC-12

    Arcus Biosciences

    Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer

    phase 1 other active

    1 trial
  8. ARC-20

    Arcus Biosciences

    Solid Tumors, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial
  9. Casdatifan

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    3 trials
  10. Domvanalimab

    Arcus Biosciences

    Solid Tumor, Unspecified, Adult

    phase 1 small molecule completed

    1 trial
  11. Etrumadenant

    Arcus Biosciences

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial
  12. Etrumadenant

    Arcus Biosciences

    Non Small Cell Lung Cancer Metastatic

    phase 1 small molecule completed

    1 trial
  13. Etrumadenant

    Arcus Biosciences

    TNBC - Triple-Negative Breast Cancer

    phase 1 small molecule completed

    1 trial
  14. Etrumadenant

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    2 trials
  15. Quemliclustat

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    1 trial
  16. Zimberelimab

    Arcus Biosciences

    Head and Neck Cancer

    phase 1 small molecule terminated

    1 trial
  17. Zimberelimab

    Arcus Biosciences

    Glioblastoma

    phase 1 small molecule active

    1 trial
  18. [14C]-etrumadenant

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    1 trial
  19. casdatifan

    Arcus Biosciences

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial
  20. etrumadenant

    Arcus Biosciences

    GastroEsophageal Cancer

    phase 1 small molecule completed

    1 trial
  21. zanzalintinib

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial
  22. zimberelimab

    Arcus Biosciences

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Arcus Biosciences have?

22 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.